Study on the Use Effectiveness of the Norepinefrina and Serotonin Reuptake Inhibitors in the Obesity Treatment (Sibutramine®)

Detalhes bibliográficos
Autor(a) principal: Ferreira, Luciano Ferreira
Data de Publicação: 2009
Outros Autores: Gomes, Elenice Gomes
Tipo de documento: Artigo
Idioma: por
Título da fonte: Saúde e Pesquisa (Online)
Texto Completo: https://periodicos.unicesumar.edu.br/index.php/saudpesq/article/view/911
Resumo: The obesity is a chronic illness where its prevalence is growing up during the decades. For this reason, it has become diversified the weight reduction treatment mainly in the pharmacologic utilization. So the objective of this research in to evaluate the effectiveness of sibutramine hydrochloride monohydrate in pharmacologic therapy anti-obesity from two to four months. It has been analyzed 487 patient’s dossier who submitted themselves in the pharmacologic treatment for loss of weight in 2003. It had been selected patients that had used sibutramine in its treatment and subsequently distributed in two groups (sibutramine and sibutramine+fluoxetine), that it was composed for 41 and 21 patients, respectively. In agreement the treatment time we can observe that the sibutramine presented an average weight loss of 4,9Kg, 6,6Kg and 9,6Kg in 2, 3 and 4 months respectively, 3,3Kg, 3,6Kg, and 1,7Kg in sibutramine plus fluoxetine groups among 2, 3 and 4 months. In consequence the IMC showed with a proportional reduction, but the difference the IMC of the two groups enter when comparing our results with other studies we can conclude that the sibutramine showed efficiency in the obesity treatment.
id CESUMAR-1_8c26fe45f15b442e2a9eadd72def6028
oai_identifier_str oai:ojs.pkp.sfu.ca:article/911
network_acronym_str CESUMAR-1
network_name_str Saúde e Pesquisa (Online)
repository_id_str
spelling Study on the Use Effectiveness of the Norepinefrina and Serotonin Reuptake Inhibitors in the Obesity Treatment (Sibutramine®)Estudo sobre a Eficácia do Uso de Inibidores da Recaptação de Norepinefrina e Serotonina no Tratamento da Obesidade (Sibutramina®)ObesityTreatmentSibutramine.ObesidadeTratamentoSibutramina.The obesity is a chronic illness where its prevalence is growing up during the decades. For this reason, it has become diversified the weight reduction treatment mainly in the pharmacologic utilization. So the objective of this research in to evaluate the effectiveness of sibutramine hydrochloride monohydrate in pharmacologic therapy anti-obesity from two to four months. It has been analyzed 487 patient’s dossier who submitted themselves in the pharmacologic treatment for loss of weight in 2003. It had been selected patients that had used sibutramine in its treatment and subsequently distributed in two groups (sibutramine and sibutramine+fluoxetine), that it was composed for 41 and 21 patients, respectively. In agreement the treatment time we can observe that the sibutramine presented an average weight loss of 4,9Kg, 6,6Kg and 9,6Kg in 2, 3 and 4 months respectively, 3,3Kg, 3,6Kg, and 1,7Kg in sibutramine plus fluoxetine groups among 2, 3 and 4 months. In consequence the IMC showed with a proportional reduction, but the difference the IMC of the two groups enter when comparing our results with other studies we can conclude that the sibutramine showed efficiency in the obesity treatment.A obesidade é uma doença crônica, e sua prevalência vem crescendo nas últimas décadas. Por esse motivo, torna-se diversificado o tratamento para a redução de peso, principalmente no que diz respeito à utilização farmacológica. Assim, o objetivo desta pesquisa é avaliar a eficácia do cloridrato monohidratado de sibutramina na terapia farmacológica anti-obesidade no período de 2 a 4 meses. Foram analisados 487 prontuários de pacientes que se submeteram ao tratamento farmacológico para perda de peso no ano de 2003. Destes foram selecionados os pacientes que utilizaram a sibutramina em seu tratamento e subsequente distribuídos em dois grupos (sibutramina e sibutramina+fluoxetina) que foram compostos por 41 e 21 pacientes, respectivamente. De acordo com o tempo de tratamento pode-se observar que o grupo sibutramina apresentou uma média de perda de peso de 4,9Kg, 6,6Kg e 9,6Kg em 2, 3 e 4 meses, respectivamente, para 3,3Kg, 3,6Kg e 1,7Kg no grupo sibutramina+ fluoxetina em 2, 3 e 4 meses. Em consequência o IMC mostrou-se com uma redução proporcional, porém a diferença entre o IMC dos dois grupos, não foi significativa. Assim ao compararmos os resultados com outros estudos pode-se concluir que a sibutramina mostrou-se eficaz no tratamento para a obesidade.Universidade Cesumar - UniCesumar2009-10-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionAvaliado por Paresapplication/pdfhttps://periodicos.unicesumar.edu.br/index.php/saudpesq/article/view/911Saúde e Pesquisa; Vol 2 No 3 (2009): set./dez.Saúde e Pesquisa; v. 2 n. 3 (2009): set./dez.2176-9206reponame:Saúde e Pesquisa (Online)instname:Cesumar Diretoria de Pesquisainstacron:CESUMARporhttps://periodicos.unicesumar.edu.br/index.php/saudpesq/article/view/911/896Ferreira, Luciano FerreiraGomes, Elenice Gomesinfo:eu-repo/semantics/openAccess2022-05-23T18:01:54Zoai:ojs.pkp.sfu.ca:article/911Revistahttps://periodicos.unicesumar.edu.br/index.php/saudpesqPUBhttps://periodicos.unicesumar.edu.br/index.php/saudpesq/oainaep@cesumar.br2176-92061983-1870opendoar:2022-05-23T18:01:54Saúde e Pesquisa (Online) - Cesumar Diretoria de Pesquisafalse
dc.title.none.fl_str_mv Study on the Use Effectiveness of the Norepinefrina and Serotonin Reuptake Inhibitors in the Obesity Treatment (Sibutramine®)
Estudo sobre a Eficácia do Uso de Inibidores da Recaptação de Norepinefrina e Serotonina no Tratamento da Obesidade (Sibutramina®)
title Study on the Use Effectiveness of the Norepinefrina and Serotonin Reuptake Inhibitors in the Obesity Treatment (Sibutramine®)
spellingShingle Study on the Use Effectiveness of the Norepinefrina and Serotonin Reuptake Inhibitors in the Obesity Treatment (Sibutramine®)
Ferreira, Luciano Ferreira
Obesity
Treatment
Sibutramine.
Obesidade
Tratamento
Sibutramina.
title_short Study on the Use Effectiveness of the Norepinefrina and Serotonin Reuptake Inhibitors in the Obesity Treatment (Sibutramine®)
title_full Study on the Use Effectiveness of the Norepinefrina and Serotonin Reuptake Inhibitors in the Obesity Treatment (Sibutramine®)
title_fullStr Study on the Use Effectiveness of the Norepinefrina and Serotonin Reuptake Inhibitors in the Obesity Treatment (Sibutramine®)
title_full_unstemmed Study on the Use Effectiveness of the Norepinefrina and Serotonin Reuptake Inhibitors in the Obesity Treatment (Sibutramine®)
title_sort Study on the Use Effectiveness of the Norepinefrina and Serotonin Reuptake Inhibitors in the Obesity Treatment (Sibutramine®)
author Ferreira, Luciano Ferreira
author_facet Ferreira, Luciano Ferreira
Gomes, Elenice Gomes
author_role author
author2 Gomes, Elenice Gomes
author2_role author
dc.contributor.author.fl_str_mv Ferreira, Luciano Ferreira
Gomes, Elenice Gomes
dc.subject.por.fl_str_mv Obesity
Treatment
Sibutramine.
Obesidade
Tratamento
Sibutramina.
topic Obesity
Treatment
Sibutramine.
Obesidade
Tratamento
Sibutramina.
description The obesity is a chronic illness where its prevalence is growing up during the decades. For this reason, it has become diversified the weight reduction treatment mainly in the pharmacologic utilization. So the objective of this research in to evaluate the effectiveness of sibutramine hydrochloride monohydrate in pharmacologic therapy anti-obesity from two to four months. It has been analyzed 487 patient’s dossier who submitted themselves in the pharmacologic treatment for loss of weight in 2003. It had been selected patients that had used sibutramine in its treatment and subsequently distributed in two groups (sibutramine and sibutramine+fluoxetine), that it was composed for 41 and 21 patients, respectively. In agreement the treatment time we can observe that the sibutramine presented an average weight loss of 4,9Kg, 6,6Kg and 9,6Kg in 2, 3 and 4 months respectively, 3,3Kg, 3,6Kg, and 1,7Kg in sibutramine plus fluoxetine groups among 2, 3 and 4 months. In consequence the IMC showed with a proportional reduction, but the difference the IMC of the two groups enter when comparing our results with other studies we can conclude that the sibutramine showed efficiency in the obesity treatment.
publishDate 2009
dc.date.none.fl_str_mv 2009-10-08
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Avaliado por Pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://periodicos.unicesumar.edu.br/index.php/saudpesq/article/view/911
url https://periodicos.unicesumar.edu.br/index.php/saudpesq/article/view/911
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://periodicos.unicesumar.edu.br/index.php/saudpesq/article/view/911/896
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Cesumar - UniCesumar
publisher.none.fl_str_mv Universidade Cesumar - UniCesumar
dc.source.none.fl_str_mv Saúde e Pesquisa; Vol 2 No 3 (2009): set./dez.
Saúde e Pesquisa; v. 2 n. 3 (2009): set./dez.
2176-9206
reponame:Saúde e Pesquisa (Online)
instname:Cesumar Diretoria de Pesquisa
instacron:CESUMAR
instname_str Cesumar Diretoria de Pesquisa
instacron_str CESUMAR
institution CESUMAR
reponame_str Saúde e Pesquisa (Online)
collection Saúde e Pesquisa (Online)
repository.name.fl_str_mv Saúde e Pesquisa (Online) - Cesumar Diretoria de Pesquisa
repository.mail.fl_str_mv naep@cesumar.br
_version_ 1754122531549216768

Registros relacionados